Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Benitec Biopharma (BNTC) Cost of Revenue (2019 - 2024)

Benitec Biopharma has reported Cost of Revenue over the past 6 years, most recently at $3000.0 for Q1 2024.

  • Quarterly results put Cost of Revenue at $3000.0 for Q1 2024, changed N/A from a year ago — trailing twelve months through Dec 2024 was $3000.0 (down 97.2% YoY), and the annual figure for FY2024 was $108000.0, changed.
  • Cost of Revenue reached $3000.0 in Q1 2024 per BNTC's latest filing, up from $1000.0 in the prior quarter.
  • Across five years, Cost of Revenue topped out at $134000.0 in Q3 2020 and bottomed at -$48000.0 in Q2 2020.
  • Median Cost of Revenue over the past 5 years was $8000.0 (2021), compared with a mean of $27900.0.
  • The largest annual shift saw Cost of Revenue tumbled 93.79% in 2020 before it surged 800.0% in 2022.
  • Over 5 years, Cost of Revenue stood at $19000.0 in 2020, then crashed by 94.74% to $1000.0 in 2021, then soared by 800.0% to $9000.0 in 2022, then crashed by 88.89% to $1000.0 in 2023, then soared by 200.0% to $3000.0 in 2024.
  • Business Quant data shows Cost of Revenue for BNTC at $3000.0 in Q1 2024, $1000.0 in Q4 2023, and $106000.0 in Q3 2023.